Physician profile
Alison Redding
NPI 1205398245
$1,193.22
in general payments reported to CMS, 2019-2025
24 companies · $224 in 2025
The $224 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $17.14 · 2023: $474 · 2024: $478 · 2025: $224.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,153 · Education: $23.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,152.76 |
| Education | $23.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $277.01 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $87.99 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $85.37 | 2023-2025 | Rexulti |
| Inspire Medical Systems, INC. | $72.03 | 2024 | Inspire |
| Sumitomo Pharma America, INC. | $67.59 | 2024-2025 | Gemtesa |
| Merck Sharp & Dohme LLC | $61.79 | 2023 | Verquvo, Steglatro, Steglujan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.12 | 2023-2025 | Jardiance |
| Daiichi Sankyo INC. | $46.94 | 2024 | Injectafer |
| Astrazeneca Pharmaceuticals LP | $40.55 | 2023-2024 | Farxiga, Lokelma |
| Celltrion USA INC. | $36.92 | 2023-2025 | Zymfentra, Vegzelma |
| Bayer Healthcare Pharmaceuticals INC. | $36.91 | 2024-2025 | |
| Lilly USA, LLC | $35.99 | 2023-2024 | Mounjaro, Zepbound |
| Regeneron Healthcare Solutions, INC. | $32.93 | 2025 | Dupixent |
| Amgen INC. | $32.31 | 2023-2024 | Prolia, Evenity |
| Exact Sciences Corporation | $31.17 | 2025 | The Cologuard Plus Collection Kit |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $30.65 | 2023 | |
| Xeris Pharmaceuticals, INC. | $29.80 | 2023-2024 | Gvoke Hypopen |
| Inari Medical, INC. | $21.84 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Ardelyx, INC. | $21.78 | 2023 | Ibsrela |
| Janssen Biotech, INC. | $19.09 | 2023 | Stelara |
| Intercept Pharmaceuticals, INC. | $18.88 | 2023 | Ocaliva |
| Janssen Pharmaceuticals, INC | $17.14 | 2022 | |
| Shield Therapeutics INC | $14.16 | 2023 | Accrufer |
| Tandem Diabetes Care, INC. | $13.26 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alison Redding listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.